Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dutch biotech gets $87.5m advance on $600m ticket to Pfizer

This article was originally published in Scrip

Executive Summary

The future of AM Pharma is now largely in the hands of clinical and business decision-makers at Big Pharma. The Dutch biotech announced late on 11 May that Pfizer had spent $87.5m on an option to acquire the company for $600m. The option matures when the Phase II clinical trial in Acute Kidney Injury (AKI) of AM Pharma's lead product, recombinant alkaline phosphatase (recAP) is complete, sometime after the end of 2016. The option fee will go straight to shareholders, CEO Erik van den Berg told Scrip.

You may also be interested in...



AM-Pharma Raises €116m To Finance Solo Phase III Trial

Following Pfizer’s decision not to take up an option to acquire the Dutch company, AM-Pharma has returned to the venture capital market to get backing for a single pivotal Phase III trial of reCAP in acute kidney injury.

Gender Diversity In Pharma: Caught Between Desire And Reality

Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete. 

Women In High Places: Slow Progress In Pharma

With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.

Topics

Related Companies

UsernamePublicRestriction

Register

SC028680

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel